Praluent (Alirocumab) Cost in Hawaii 2026: Prices, Insurance, and Savings

What Praluent Costs at Hawaii Pharmacies in 2026

The manufacturer list price for Praluent in Hawaii is $580 per month, matching the national wholesale acquisition cost set by Regeneron and Sanofi. Retail pharmacies across the islands charge approximately this same amount for cash-pay customers without insurance or discount card assistance.

That $580 figure covers either the 75 mg or 150 mg prefilled pen, administered as a subcutaneous injection every two weeks [1]. Patients who require the higher 300 mg monthly dose (given as two 150 mg injections on the same day) pay the same monthly amount. The price has remained stable since Regeneron and Sanofi reduced the list price by 60% from $1,450 per month in 2019, a move the companies made after payers imposed strict utilization management barriers that limited patient access [2]. Hawaii's geographic isolation does not add a retail markup for this drug because specialty pharmacies, which handle most Praluent dispensing, use centralized distribution networks.

For context, Praluent's annual cost of $6,960 is lower than that of inclisiran (Leqvio), which carries a list price of approximately $3,250 per injection given twice yearly ($6,500 per year) but requires in-office administration [3]. Evolocumab (Repatha), the other PCSK9 inhibitor on the market, has a comparable list price of roughly $580 per month.

Hawaii Medicaid Does Not Cover Praluent

Hawaii Medicaid does not include Praluent on its preferred drug list. Patients enrolled in Med-QUEST, Hawaii's Medicaid managed care program, cannot obtain coverage for alirocumab through standard formulary channels.

This gap affects a significant population. Approximately 400,000 Hawaii residents receive Medicaid benefits, and familial hypercholesterolemia (FH) affects an estimated 1 in 250 people according to the CDC [4]. Patients who need PCSK9 inhibitor therapy and rely on Medicaid may explore several alternatives. Maximally tolerated statin therapy combined with ezetimibe remains the first-line approach recommended by the 2018 AHA/ACC cholesterol guideline before adding a PCSK9 inhibitor [5]. Bempedoic acid (Nexletol), an oral LDL-lowering agent, has gained broader formulary placement and may be covered under Med-QUEST where PCSK9 inhibitors are not.

Patients with heterozygous FH and LDL cholesterol that remains above goal despite maximum oral therapy should ask their cardiologist or lipid specialist to submit a medical exception request to their Med-QUEST health plan. These requests require documentation of statin intolerance or treatment failure. Approval is not guaranteed, but it is the only administrative pathway within Medicaid to access this drug class.

Which Commercial Insurance Plans Cover Praluent in Hawaii

Most major commercial insurers operating in Hawaii will cover Praluent, but only after prior authorization and step therapy requirements are met. HMSA (Hawaii Medical Service Association), the state's largest health insurer covering roughly 50% of the commercially insured population, requires documentation of LDL-C levels, statin history, and diagnosis before approving coverage.

The 2018 AHA/ACC guideline recommends adding a PCSK9 inhibitor for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [5]. Insurers typically mirror this threshold. A standard prior authorization for Praluent in Hawaii requires:

• Diagnosis of heterozygous FH or established atherosclerotic cardiovascular disease (ASCVD)
• Trial and failure (or documented intolerance) of at least one high-intensity statin
• Current or prior use of ezetimibe
• Fasting LDL-C lab result showing levels above treatment goal despite oral therapy
• Prescription from or consultation with a cardiologist or lipid specialist

Kaiser Permanente Hawaii, UnitedHealthcare, and Aetna plans available through the state's Affordable Care Act marketplace follow similar authorization criteria. Approval periods typically last 6 to 12 months before requiring renewal documentation. Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has stated: "Prior authorization remains the single biggest barrier to PCSK9 inhibitor access in the United States, even for patients who clearly meet guideline criteria" [6].

How the Regeneron/Sanofi Savings Card Works in Hawaii

The MyPraluent copay card, offered by Regeneron and Sanofi, can reduce out-of-pocket costs to $0 per month for commercially insured patients in Hawaii. The card is accepted at specialty and retail pharmacies throughout the state.

Eligible patients must have commercial (private) insurance that covers Praluent. The savings card covers the difference between the patient's copay or coinsurance amount and $0, up to a maximum annual benefit. Patients with government insurance (Medicare, Medicaid, Tricare, VA) are not eligible for the copay card per federal anti-kickback regulations.

To enroll, patients visit the manufacturer's patient support website or call the MyPraluent support line. The card is linked to the patient's prescription and activated at the pharmacy. Processing takes the form of a secondary claim after the primary insurance adjudicates. Most Hawaii specialty pharmacies, including CVS Specialty, Optum Specialty, and Accredo, are familiar with this workflow.

For Medicare Part D enrollees, who cannot use the copay card, out-of-pocket costs depend on formulary tier and plan phase. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect in 2025, Medicare patients' total Part D spending is now capped regardless of individual drug costs [7]. This provision meaningfully reduces the financial burden of Praluent for seniors on Medicare, even without manufacturer copay assistance.

Compounded Alirocumab Through 503A Pharmacies in Hawaii

Compounded alirocumab is legal and available in Hawaii through licensed 503A compounding pharmacies. These pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription [8].

A 503A pharmacy compounds each prescription individually for a named patient. This differs from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. In Hawaii, 503A pharmacies must hold a valid state pharmacy license and comply with both federal and Hawaii Board of Pharmacy compounding regulations.

The cost of compounded alirocumab varies by pharmacy but has been reported at significantly lower price points than the branded product. Some patients report paying nothing out of pocket through certain compounding arrangements, though pricing is set by each individual pharmacy. Patients considering compounded alirocumab should verify several things with their provider: the pharmacy's licensure status, the source and purity of raw alirocumab material, storage and cold-chain handling (PCSK9 inhibitors require refrigeration at 2 to 8 degrees Celsius), and whether their insurance will process a claim for a compounded biologic.

The FDA's guidance on compounding notes that compounded drugs are not FDA-approved and do not undergo the same manufacturing oversight as commercially manufactured products [8]. Prescribers and patients must weigh the cost savings against these regulatory differences.

Clinical Evidence Supporting Alirocumab Use

The clinical case for alirocumab rests primarily on the ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018. This randomized, double-blind, placebo-controlled study enrolled 18,924 patients who had experienced an acute coronary syndrome (ACS) event within the prior 1 to 12 months [1].

At 48 months of follow-up, alirocumab reduced the composite primary endpoint of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% compared to placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) [1]. The absolute risk reduction was 1.6 percentage points. All-cause mortality showed a nominal reduction (3.5% vs. 4.1%, HR 0.85 to 95% CI 0.73 to 0.98), though this was a secondary endpoint and did not meet the hierarchical testing threshold.

Mean LDL-C at month 4 was 53.3 mg/dL in the alirocumab group versus 101.4 mg/dL in the placebo group. Patients with baseline LDL-C of 100 mg/dL or higher derived the greatest absolute benefit.

The 2018 AHA/ACC cholesterol management guideline incorporated these findings, recommending PCSK9 inhibitors as add-on therapy for very high-risk ASCVD patients with LDL-C persistently at or above 70 mg/dL despite maximally tolerated statin and ezetimibe [5]. Dr. Robert Giugliano, a cardiologist at Brigham and Women's Hospital and co-author of several PCSK9 inhibitor analyses, has noted: "The ODYSSEY OUTCOMES data established that lowering LDL cholesterol with alirocumab after an acute coronary event translates into fewer heart attacks, strokes, and deaths" [1].

Telehealth Prescribing of Praluent in Hawaii

Hawaii permits telehealth prescribing of Praluent. Patients can receive an alirocumab prescription from a licensed provider through a video or audio visit without an in-person examination, consistent with Hawaii's telehealth parity laws.

This is particularly relevant for residents of neighbor islands (Maui, Kauai, Hawaii Island, Molokai, Lanai) who may not have local access to a lipid specialist or cardiologist. A telehealth consultation with a board-certified provider can include review of lipid panels, cardiovascular history, and current medications. The prescriber can then submit the prior authorization paperwork to the patient's insurer and send the prescription to a specialty pharmacy that ships directly to the patient's home.

Hawaii's telehealth framework, codified in Hawaii Revised Statutes §453-1.3, requires that the provider be licensed in the state or hold a valid telehealth registration. HealthRX connects patients in Hawaii with licensed clinicians who can evaluate candidacy for PCSK9 inhibitor therapy and manage the prior authorization process.

Cheapest Ways to Get Praluent in Hawaii

Patients looking to minimize out-of-pocket Praluent costs in Hawaii have several options, ranked by typical savings.

Manufacturer copay card. For commercially insured patients, the MyPraluent savings card often brings the copay to $0. This is the single most effective cost-reduction tool for eligible patients.

Specialty pharmacy shopping. Prices are relatively uniform for branded Praluent, but some specialty pharmacies offer modest discounts or have negotiated lower rates with specific insurance plans. Checking with HMSA's preferred specialty pharmacy network may yield lower cost-sharing.

503A compounding. Compounded alirocumab from a licensed 503A pharmacy in Hawaii may cost substantially less than the branded product. Discuss this option with your prescriber if cost is a barrier.

Patient assistance programs. Regeneron and Sanofi offer a patient assistance program (PAP) for uninsured or underinsured patients who meet income criteria. Eligible patients may receive Praluent at no cost.

Medicare Part D optimization. Seniors should review Part D plan formularies during annual open enrollment. Some plans place Praluent on a lower specialty tier. With the $2,000 annual out-of-pocket cap now in effect, even specialty-tier placement results in capped annual spending [7].

Alternative PCSK9 approaches. If alirocumab remains unaffordable, inclisiran (Leqvio) requires only two injections per year after a loading dose and is administered in-office, which may simplify insurance billing as a medical benefit rather than a pharmacy benefit [3].